Efficacy and side effects of risperidone, quetiapine and olanzapine in the treatment of Shisheh psychosis

Phase 3

Recruiting

Conditions: Other stimulant related disorders
psychosis symptoms due to Shisheh.

Registration Number: IRCT20160530028173N5

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 45

Inclusion Criteria

Having criteria for glass-induced psychosis disorder based on DSM-5 (through clinical interview by psychiatrist).
Treated with one of the antipsychotics risperidone, quetiapine and olanzapine
No other psychiatric disorders
Willingness of an individual or family (conscious consent) to participate in the study
Minimum age 18
If you have a history of drug treatment for the above disorder, at least three weeks have passed since you stopped taking the drug

Exclusion Criteria

History of mental disorders
History of epilepsy
History of brain trauma
Taking drugs other than target group treatment drugs
Unwillingness of the patient or the family to continue cooperating in the study for any reason
Incomplete questionnaires
If a sample has other psychiatric disorders, including personality disorders, it will be excluded from the plan and will continue its routine treatment.
Incidence of drug complications based on the AIMS scale

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Positive Symptoms Severity. Timepoint: Before the intervention, one month after the intervention. Method of measurement: PANSS positive and negative symptom scale.;Negative Symptoms Severity. Timepoint: Before the intervention, one month after the intervention. Method of measurement: PANSS positive and negative symptom scale.

Secondary Outcome Measures